COMMUNIQUÉS West-GlobeNewswire

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
21/07/2026
PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties [...]
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
21/07/2026
REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a [...]
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
21/07/2026
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it has signed a regional agreement [...]
Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles
21/07/2026
Flavors with rare cannabinoid formulations from SOURZ by Spinach®, along with a new limited-time offer flavor, are now available in the popular multipack format TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- Cronos Group [...]
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
21/07/2026
CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation [...]
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
21/07/2026
MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
21/07/2026
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE [...]
Applied Biologics Initiates Multi-Center Real-World Outcomes Study of XWRAP® Across Chronic Wound Types
21/07/2026
SCOTTSDALE, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
21/07/2026
Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- [...]
Kraig Biocraft Laboratories CEO Kim Thompson Featured in Just Style, a Leading Global Apparel Industry Trade Publication
21/07/2026
Interview Spotlights Company's Commercial-Scale Production Progress and Path to Transforming the Global Textile Industry ANN ARBOR, Mich., July 21, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB [...]
Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange
21/07/2026
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today [...]
Allogenetics Appoints Dr. Jeroen Rovers as Chief Medical Officer
21/07/2026
Seasoned executive leader and physician-scientist brings deep immunology and transplant medicine experience Company strengthens executive team as it advances its lead ex vivo donor-organ therapy ALG-115 toward clinical [...]
Transactions in connection with share buy-back program
21/07/2026
Company announcement no. 26 - 26 21 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting
21/07/2026
PRESS RELEASE Magnitude of EO2463-induced CD8 T-cell expansion during monotherapy statistically significantly associated with longer progression-free survival (PFS) in patients with indolent non-Hodgkin lymphoma (iNHL) [...]
OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA
21/07/2026
Feedback from the U.S. Food and Drug Administration (FDA) supports acceleration of OMT-28’s development path directly into a pivotal Phase 3 study With the vast majority of PMD patients having no FDA-approved [...]
Carbios reaches milestone of 100 batches at its Industrial demonstration plant and expands its licensing offering to the textile market
21/07/2026
Validation of the "Fiber-to-Fiber" biorecycling process under conditions representative of industrial operations 100 th batch 1 successfully produced at the Clermont-Ferrand demonstration plant More than 95% conversion [...]
Carbios franchit le cap des 100 batchs produits au sein de son démonstrateur industriel et étend son offre de licences au marché textile
21/07/2026
Validation du procédé de biorecyclage « fibre-à-fibre », dans des conditions représentatives d’une exploitation industrielle 100 ème batch 1 produit avec succès au sein du démonstrateur de Clermont-Ferrand Plus de 95 % [...]
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
21/07/2026
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc 1 , +3% USD), with core operating income 1 flat (cc and USD) Sales growth driven by priority brands including Kisqali (+43% cc), Kesimpta [...]
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
21/07/2026
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the [...]

Pages